LSV Asset Management’s United Therapeutics UTHR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$236M Sell
398,665
-9,400
-2% -$4.68M 0.51% 60
2025
Q4
$199M Sell
408,065
-278,645
-41% -$130M 0.43% 75
2025
Q3
$288M Sell
686,710
-177,913
-21% -$59.8M 0.64% 45
2025
Q2
$248M Sell
864,623
-37,700
-4% -$11.3M 0.58% 51
2025
Q1
$278M Sell
902,323
-6,401
-0.7% -$2.19M 0.67% 37
2024
Q4
$321M Sell
908,724
-60,741
-6% -$22.3M 0.74% 29
2024
Q3
$347M Buy
969,465
+3,095
+0.3% +$1.05M 0.74% 33
2024
Q2
$308M Buy
966,370
+436,851
+82% +$116M 0.67% 36
2024
Q1
$122M Buy
529,519
+152,151
+40% +$34.3M 0.25% 125
2023
Q4
$83M Sell
377,368
-5,700
-1% -$1.31M 0.18% 164
2023
Q3
$86.5M Buy
383,068
+3,700
+1% +$852K 0.2% 153
2023
Q2
$83.7M Sell
379,368
-18,840
-5% -$4.17M 0.18% 166
2023
Q1
$89.2M Sell
398,208
-13,810
-3% -$3.4M 0.2% 153
2022
Q4
$115M Sell
412,018
-153,504
-27% -$38.8M 0.25% 125
2022
Q3
$118M Sell
565,522
-25,900
-4% -$5.79M 0.28% 115
2022
Q2
$139M Sell
591,422
-2,980
-0.5% -$606K 0.3% 105
2022
Q1
$107M Buy
594,402
+57,350
+11% +$10.9M 0.2% 151
2021
Q4
$116M Buy
537,052
+12,766
+2% +$2.51M 0.21% 150
2021
Q3
$96.8M Sell
524,286
-29,340
-5% -$5.78M 0.17% 162
2021
Q2
$99.3M Sell
553,626
-19,770
-3% -$3.77M 0.17% 169
2021
Q1
$95.9M Sell
573,396
-25,420
-4% -$4.24M 0.16% 170
2020
Q4
$90.9M Buy
598,816
+40,860
+7% +$5.36M 0.17% 164
2020
Q3
$56.4M Buy
557,956
+39,922
+8% +$4.38M 0.12% 212
2020
Q2
$62.7M Buy
518,034
+175,287
+51% +$19.7M 0.13% 186
2020
Q1
$32.5M Buy
342,747
+146,354
+75% +$13.9M 0.08% 248
2019
Q4
$17.3M Buy
196,393
+67,534
+52% +$5.94M 0.03% 402
2019
Q3
$10.3M Sell
128,859
-84,893
-40% -$6.84M 0.02% 454
2019
Q2
$16.7M Sell
213,752
-317,463
-60% -$29.7M 0.03% 401
2019
Q1
$62.3M Sell
531,215
-85,334
-14% -$9.94M 0.1% 213
2018
Q4
$67.1M Buy
616,549
+106,460
+21% +$12.3M 0.12% 191
2018
Q3
$65.2M Buy
510,089
+29,600
+6% +$3.66M 0.1% 220
2018
Q2
$54.4M Buy
480,489
+60,149
+14% +$6.61M 0.09% 242
2018
Q1
$47.2M Buy
420,340
+146,194
+53% +$18.6M 0.08% 250
2017
Q4
$40.6M Buy
274,146
+102,565
+60% +$13M 0.06% 272
2017
Q3
$20.1M Sell
171,581
-300,239
-64% -$38.3M 0.03% 372
2017
Q2
$61.2M Sell
471,820
-791,858
-63% -$98.8M 0.11% 200
2017
Q1
$171M Sell
1,263,678
-18,400
-1% -$2.79M 0.31% 101
2016
Q4
$184M Buy
1,282,078
+15,418
+1% +$1.97M 0.34% 92
2016
Q3
$150M Buy
1,266,660
+36,010
+3% +$4.33M 0.29% 104
2016
Q2
$130M Buy
1,230,650
+50,700
+4% +$5.66M 0.27% 107
2016
Q1
$131M Buy
1,179,950
+475,495
+67% +$60.2M 0.28% 108
2015
Q4
$110M Buy
704,455
+600,162
+575% +$87.4M 0.24% 119
2015
Q3
$13.7M Sell
104,293
-1,218,903
-92% -$195M 0.03% 324
2015
Q2
$230M Sell
1,323,196
-643,540
-33% -$116M 0.48% 72
2015
Q1
$339M Sell
1,966,736
-191,048
-9% -$29.1M 0.7% 36
2014
Q4
$279M Buy
2,157,784
+3,996
+0.2% +$515K 0.58% 56
2014
Q3
$277M Buy
2,153,788
+258,460
+14% +$26.6M 0.61% 49
2014
Q2
$168M Buy
1,895,328
+150,678
+9% +$14.5M 0.37% 93
2014
Q1
$164M Sell
1,744,650
-726,463
-29% -$74.3M 0.38% 91
2013
Q4
$279M Sell
2,471,113
-111,348
-4% -$10M 0.66% 45
2013
Q3
$204M Sell
2,582,461
-34,900
-1% -$2.55M 0.52% 71
2013
Q2
$172M Buy
+2,617,361
New +$169M 0.46% 73

Other funds holding UTHR

LSV Asset Management's UTHR Position: Q1 2026 in Review

LSV Asset Management reduced its United Therapeutics (UTHR) stake by 2.3% in Q1 2026, selling an estimated $4.68M and leaving 398,665 shares worth $236M. The position accounts for 0.51% of the portfolio, ranked #60.

LSV Asset Management first reported a position in UTHR in Q2 2013 and has held it in 52 quarters since. The position peaked at $347M in Q3 2024. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • LSV Asset Management held 398,665 shares of United Therapeutics worth $236M as of Q1 2026.
  • LSV Asset Management sold 9,400 United Therapeutics shares in Q1 2026, an estimated $4.68M.
  • United Therapeutics made up 0.51% of LSV Asset Management's portfolio in Q1 2026, its #60 holding.
  • LSV Asset Management first reported a position in United Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • LSV Asset Management's United Therapeutics position peaked at $347M in Q3 2024.
  • 850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on LSV Asset Management's 13F filing for Q1 2026, filed 11 May 2026.